SNY Sanofi

41.24
-0.07  -0%
Previous Close 41.31
Open 41.17
Price To Book 1.54
Market Cap 102766506617
Shares 2,491,919,394
Volume 205,007
Short Ratio
Av. Daily Volume 1,041,295

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2019.
Sutimlimab (BIVV009) - Cardinal
Cold agglutinin disease
Phase 3 data due 4Q 2019.
Sutimlimab (BIVV009) - Cadenza
Cold agglutinin disease
FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
Approval announced December 11, 2017.
Admelog (insulin lispro injection)
Diabetes
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial commenced 4Q 2017. Data due 2020.
Efpeglenatide
Type 2 diabetes
Phase 3 data due 4Q 2019.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
PDUFA date for sBLA filing April 28, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Sotagliflozin
Type 1 Diabetes
Phase 3 data February 5, 2019 met primary endpoint. BLA filing 2Q 2019.
Isatuximab
Refractory Multiple Myeloma
Phase 3 enrolment commenced November 2016.
NeoGAA - COMET
Pompe disease
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 data due 4Q 2019.
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
Data due 2020.
Cemiplimab
Basal cell carcinoma
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
PDUFA date under priority review June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 3 trial commenced September 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL issued March 22, 2019.
Sotagliflozin
Type 1 Diabetes
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Phase 3 data due 4Q 2019.
Sotagliflozin
Type 2 Diabetes
Approved January 23, 2019.
Fluzone Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
PDUFA date under priority review May 1, 2019.
Dengvaxia
Dengue
FDA Approval announced February 6, 2019.
Caplacizumab
Acquired thrombotic thrombocytopenic purpura (aTTP)

Latest News

  1. Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
  2. Sanofi Named One of America's Best Employers by Forbes
  3. Boehringer's operating income flat as integration costs weigh
  4. World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe
  5. Does Sanofi (EPA:SAN) Have A Good P/E Ratio?
  6. Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis
  7. Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)
  8. 3 Biotech Stocks That Doubled After Hitting Bottom in 2018
  9. Sanofi sets a fixed price of insulin at $99 per month for some patients
  10. Sanofi to cut U.S. insulin costs for some patients to $99 per month
  11. Sanofi provides unprecedented access to its insulins for one set monthly price
  12. Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
  13. Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
  14. Alnylam trades partner Sanofi for Regeneron in $800M deal
  15. Inovio Closes Enrollment in Brain Cancer Study Before Time
  16. Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
  17. Sanofi: Availability of the Pre-quarterly Results Communication
  18. Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates